Segment Information (Tables)

3 Months Ended

Mar. 27, 2026

Segment Reporting [Abstract]

Segment Results

Detailed segment data for the three-month periods ended March 27, 2026 and March 28, 2025 is as follows ($ in millions):

	Biotechnology		Life Sciences		Diagnostics		Total Reportable Segments		Other(a)		Total
For the Three-Month Period Ended March 27, 2026:
Sales	$	1,797	$	1,737	$	2,417	$	5,951	$	—	$	5,951
Less:
Depreciation	(40)		(48)		(102)		(190)		(3)		(193)
Amortization of intangible assets	(234)		(152)		(48)		(434)		—		(434)
Other segment items(b)	(989)		(1,312)		(1,593)		(3,894)		(86)		(3,980)
Operating profit	$	534	$	225	$	674	$	1,433	$	(89)	$	1,344
For the Three-Month Period Ended March 28, 2025:
Sales	$	1,612	$	1,680	$	2,449	$	5,741	$	—	$	5,741
Less:
Depreciation	(34)		(45)		(100)		(179)		(2)		(181)
Amortization of intangible assets	(213)		(149)		(48)		(410)		—		(410)
Other segment items(b)	(924)		(1,285)		(1,583)		(3,792)		(84)		(3,876)
Operating profit (loss)	$	441	$	201	$	718	$	1,360	$	(86)	$	1,274

(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.

(b) Other segment items for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses and research and development (“R&D”) expenses, excluding in each case depreciation, amortization of intangible assets and impairments. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses.

The following table presents identifiable assets as of March 27, 2026 and December 31, 2025 ($ in millions):

	March 27, 2026		December 31, 2025
Biotechnology	$	36,697	$	37,337
Life Sciences	22,873		23,112
Diagnostics	14,657		14,748
Other	9,317		8,267
Total	$	83,544	$	83,464

The following table presents capital expenditures, gross for the three-month periods ended March 27, 2026 and March 28, 2025 ($ in millions):

	Three-Month Period Ended
	March 27, 2026		March 28, 2025
Biotechnology	$	64	$	81
Life Sciences	27		48
Diagnostics	144		115
Other	2		1
Total	$	237	$	245